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Abstract
Background: More than 50 million people around the world are investigated for tuberculosis using sputum smear
microscopy annually. This process requires repeated visits and patients often drop out.
Methods and Findings: This clinical trial of adults with cough $2 wk duration (in Ethiopia, Nepal, Nigeria, and Yemen)
compared the sensitivity/specificity of two sputum samples collected ‘‘on the spot’’ during the first visit plus one sputum
sample collected the following morning (spot-spot-morning [SSM]) versus the standard spot-morning-spot (SMS) scheme.
Analyses were per protocol analysis (PPA) and intention to treat (ITT). A sub-analysis compared just the first two smears of
each scheme, spot-spot and spot-morning. In total, 6,627 patients (3,052 SSM/3,575 SMS) were enrolled; 6,466 had culture
and 1,526 were culture-positive. The sensitivity of SSM (ITT, 70.2%, 95% CI 66.5%–73.9%) was non-inferior to the sensitivity
of SMS (PPA, 65.9%, 95% CI 62.3%–69.5%). Similarly, the specificity of SSM (ITT, 96.9%, 95% CI 93.2%–99.9%) was non-inferior
to the specificity of SMS (ITT, 97.6%, 95% CI 94.0%–99.9%). The sensitivity of spot-spot (ITT, 63.6%, 95% CI 59.7%–67.5%) was
also non-inferior to spot-morning (ITT, 64.8%, 95% CI 61.3%–68.3%), as the difference was within the selected 25% non-
inferiority limit (difference ITT = 1.4%, 95% CI 23.7% to 6.6%). Patients screened using the SSM scheme were more likely to
provide the first two specimens than patients screened with the SMS scheme (98% versus 94.2%, p,0.01). The PPA and ITT
analysis resulted in similar results.
Conclusions: The sensitivity and specificity of SSM are non-inferior to those of SMS, with a higher proportion of patients
submitting specimens. The scheme identifies most smear-positive patients on the first day of consultation.
Trial Registration: Current Controlled Trials ISRCTN53339491
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Introduction
Nine million people developed tuberculosis (TB) and 1.7 million
died from the disease in 2008 [1], with over 90% of cases occurring
in low- and middle-income countries (LMICs) [1]. Most patients in
LMICs are investigated by direct sputum smear microscopy, which,
although widely available, has low sensitivity [2] and requires the
examination of multiple specimens over several days to maximise
the identification of cases [3,4]. Most national TB programmes
(NTPs) collect specimens using a spot-morning-spot (SMS) scheme,
whereby patients provide one ‘‘on the spot’’ specimen at the time of
consultation, one specimen produced at home the morning of the
following day, and a third specimen on the spot when the patient
brings the morning specimen to the service. This scheme became
widely adopted after a study by Andrews and colleagues in the
1950s concluded that this combination identified the highest
number of patients with the lowest number of visits [5]. Since the
scheme requires at least two visits, however, patients often abandon
the diagnostic process [6–8].
A recent systematic review indicated that the first two sputum
specimens identified 95%–98% of the smear-positive cases
identified from three specimens [9]. Thus, given the excessive
workloads of many laboratories in LMICs, the World Health
Organization (WHO) recommended a reduction (from three to
two) of the number of specimens examined under certain
circumstances [10,11]. Although this change may reduce labora-
tory workloads, patients would still make the same number of visits
to the diagnostic centres because the collection of a morning
specimen obliges all patients to come back to the centre the next
day.
Andrews and colleagues’ study had reported that the yield of the
three specimens was independent of the order in which these
specimens were collected [5], and a scheme collecting three
specimens as spot-spot-morning (SSM) has recently been reported
to result in the same yield as the standard SMS scheme [12].
Although this distinction seems small, this finding may be
important, as most patients with positive smear microscopy are
identified with the first two smears, and examining two on-the-spot
smears may identify most smear-positive cases on the first day of
consultation, thus avoiding the need for patients to return the next
day. The latter report, however, had collected four specimens as
spot-spot-morning-spot to examine different permutations [12–14]
and did not explore whether a spot-spot-morning scheme would
reduce the number of patients defaulting from the diagnostic
process.
Schemes that collect specimens in an accelerated fashion may
have the potential to improve diagnostic services in LMICs by
reducing the number of visits and the number of patients
defaulting [15–17]. We therefore conducted a trial to assess
whether the sensitivity and specificity of schemes collecting most of
the on-the-spot specimens on the day of first consultation is non-
inferior to the current standard scheme, and a complementary
study that evaluates LED fluorescence microscopy within the
context of these schemes is also published in this issue [18]. These
schemes would be an important step towards making the
diagnostic process more efficient and less onerous for patients.
Methods
Study Design
This was a prospective multi-country, randomized non-
inferiority trial conducted in Ethiopia, Nepal, Nigeria, and Yemen
to determine whether a scheme collecting two sputum specimens
on the first day of consultation plus a morning specimen on the
following day (SSM) had sensitivity and specificity that are non-
inferior to the standard SSM scheme for the diagnosis of
pulmonary TB (see Text S1).
Study Sites
Participants in Ethiopia were enrolled in Bushullo Major and
Awassa Health Centres in the Southern Region. These are the
main health service providers for Awassa District. Sputum
specimens for culture were sent under appropriate conditions to
the Armauer Hansen Institute, in Addis Ababa. In Abuja, Nigeria,
patients were enrolled in Wuse District Hospital, and specimens
were processed in Zankli Medical Centre, a private hospital
endorsed as a diagnostic centre through contractual arrangement
with the NTP. In Nepal, patients were enrolled from the DOTS
Centre, Tribhuvan University Teaching Hospital, and the Dirgh
Jeevan Health Care and Research Centre, Kathmandu. Speci-
mens were processed in Tribhuvan University Health Research
Laboratory. In Yemen, patients were enrolled at the Tuberculosis
Institute in Sana’a. This institute, which houses the NTP and the
national TB reference laboratory, also provides diagnostic services
to the surrounding population and referred patients.
Inclusion and Exclusion Criteria
Patients $18 y old with cough $2 wk duration who had not
received anti-TB treatment in the previous month presenting at
the study site health service providers between 1 January 2008 and
30 March 2009 were eligible to participate.
Study Interventions and Randomization
Participants were asked to submit sputum specimens using the
standard SMS or the new SSM scheme (Figure 1). The SMS
scheme required one on-the-spot specimen at the time of the first
visit, one specimen collected at home the following morning, and
one on-the-spot specimen collected when the patient brought the
morning sample to the laboratory. The SSM scheme required one
on-the-spot specimen collected at the time of the first visit, a
second on-the-spot specimen collected one hour later, and one
morning specimen collected at home the following morning (see
CONSORT statement and STARD checklist in Texts S2 and S3).
All patients were requested to bring specimens on consecutive
days, independently of the scheme.
The schemes were block-randomized by week over a period of
12 mo. The scheme to be used each week by each centre was
allocated by block randomization. After generating a list of
random numbers ranging from 1 to 5 using Minitab Statistical
Software (http://www.minitab.com), the scheme to be used in a
specific week in each centre was allocated using a permuted block
design. Blocks of fixed size were used to permute the week
allocations (allocated as AABB, ABAB, BABA, ABBA, and BAAB,
where A was the standard and B the frontloaded scheme). The
schemes allocated were distributed to study centres concealed in
sealed envelopes. The study coordinators were unaware of the
block size and were only allowed to open the envelope at the start
of each week. The decision to randomize by week was taken to test
the study hypothesis within a context of a systems change, and it
was considered that randomization of individuals was not feasible.
The envelopes, thus, were not used to randomize individual
participants, but provided a focal point to ensure all staff were
aware of the scheme being used in a particular week. A total of 222
randomized weeks were distributed across the study sites, and of
these, 114 were allocated to the standard and 108 to the
frontloaded scheme, with a median number of patients per week
of 24 and 26 patients for the SSM and SMS schemes, respectively
(p.0.2).
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Patients were not compensated for participating in the trial and
underwent the same routine procedures undertaken under
operational conditions. Patients were screened using the routine
procedures of the outpatient clinics and were examined by a large
number of clinicians. Cough registers were not kept, given the
heavy workload of staff. Therefore, although the number of
patients with chronic cough attending the clinics should have been
similar to the number examined using smear microscopy, a small
Figure 1. CONSORT flow diagram of the study.
doi:10.1371/journal.pmed.1000443.g001
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proportion may have been treated with antibiotics or may have left
the service without notifying the staff, and are therefore
unaccounted for.
Collection and Processing of Sputum Specimens
Standardised instructions for specimen collection, based on
those used by Khan et al. [19], were given to all patients, and
specimens were collected in pre-labelled pots. The number of
patients who stopped attending and/or submitting specimens was
recorded. Specimens were assessed macroscopically, and smears
were stained using the hot Ziehl-Neelsen technique [3]. Slides
were assigned study numbers and routine laboratory numbers,
which were covered with wrap-around stickers for blinding. All
smears were then mixed before examination (1,0006) and graded
by laboratory technicians following the International Union
Against Tuberculosis and Lung Disease system [3]. The stickers
were removed only when another technician entered the results
into a logbook. One sample per patient was processed for culture.
The morning sample was selected for the majority of cases. If the
patient did not submit a morning sample, then one of the spot
specimens kept in the fridge was cultured. The specimen for
culture was concentrated (Petroff’s method) and cultured on solid
medium using the standard operating procedures of the NTP. In
Yemen and Nepal, specimens were cultured in Ogawa medium,
while specimens in Nigeria and Ethiopia were cultured in
Lowenstein-Jensen medium. Positive cultures were confirmed as
acid fast bacilli (AFB), and standard bacteriological tests (niacin
test) were used to identify the Mycobacterium tuberculosis complex.
Quality Assurance Procedures
The protocol was implemented in accordance with standard
operating procedures and in compliance with good clinical practice/
good clinical laboratory practice, and the STARD checklist is
available (Text S3). A lot quality assurance sampling scheme was used
to determine the sample size for external quality assessment (EQA),
and EQAwas conducted by twoWHO/International Union Against
Tuberculosis and Lung Disease Supranational Reference Laborato-
ries. The sample size for selecting slides for EQA was based on the
expected smear positivity rate and the number of negative smears
examined in a year in each of the four laboratories, to assure a
sensitivity of 90% relative to the controller and an accepted
discrepancy number of 2 [20]. Sampling for EQA was performed
before, during, and at the end of the study, and all sites met the pre-set
quality standard. The information recorded by the interviewer was
checked at the end of the day, and an attempt was made to contact
the patient if any data were missing. If these attempts were
unsuccessful and data was not recorded in the study laboratory
logbooks, information that was missing was specified in the text.
Sample Size and Statistical Analysis
The sample size was calculated to establish that the SSM
scheme was not inferior to the standard SMS scheme and to
achieve 90% power to detect a non-inferiority margin difference of
5% between the proportions of patients with positive culture
detected by the schemes. It was assumed that the standard
approach would identify 50% of culture-positive patients, which
was the yield observed in previous studies. The proportion of
smear-positive cases identified by the SSM scheme was assumed to
be 45% (or greater) of culture-positive patients under the null
hypothesis of inferiority. The test statistic (one-sided unpooled z-
test) was computed for the case scenario of the actual treatment
group proportion being 50%. The significance level was targeted
at 0.05 (5%). As the sample size was computed for culture-positive
patients and it was assumed that 50% of patients undergoing
screening would be culture-positive, the number of patients to be
screened was 6,784.
The statistical analysis was carried out using the Stata9
statistical computer package [21]; ‘‘svy’’ commands were used
where possible to adjust for clustering both within sites (countries)
and within blocks. The study staff, however, were not blind to the
scheme allocation, and the statistical analysis was not blinded.
Variables were summarised as frequency counts/percentages (with
two-sided confidence intervals), with the exceptions of age and
cough duration, which were summarised using means/standard
deviations and were compared between the two study arms to
explore whether the randomization had worked and the
characteristics of the patients were similar. Smears were classified
as positive when $1 AFB in 100 fields were detected. Patients
were considered smear-positive if they had $1 smear with $1
AFB, following current WHO definitions [10,11]. Culture was the
reference standard for the calculation of sensitivity and specificity.
Analysis was based on both intention to (diagnose and) treat (ITT)
analysis and per protocol analysis (PPA). Patients with missing
smears were classified according to the results available (e.g.,
patients with negative first spot, negative morning, and missing
second spot were classified as smear-negative) for the ITT analysis,
but were excluded from the PPA. The ITT analysis is presented in
the narrative of the text results for the sake of clarity, and both
ITT and PPA are described in the tables for completeness. Eight
patients allocated to the SSM scheme were examined with the
SMS scheme, and three patients allocated to the SMS scheme
were examined using the SSM scheme. These protocol violations
represent ,0.2% of the participants and mostly occurred at the
start of the week. Given that their specimens were examined
blindly, it was decided to include these patients in the scheme
under which they were examined. Two further sub-analyses were
conducted. One comprised the analysis of the first two smears of
each scheme (spot-spot [SS] versus spot-morning [SM]) using
culture as the reference standard, and the second included
individuals who volunteered information about their HIV status.
HIV counselling and testing were offered in Nigeria and Ethiopia,
following national guidelines and routine testing conditions, and
patients were asked whether they had been tested for HIV. Only
patients who volunteered this information were categorised as
HIV-positive or -negative, and the tests used varied across study
sites. HIV testing procedures for TB programmes therefore varied
by site. Testing was not available for all patients in Yemen and
Nepal, and the uptake of HIV testing varied significantly between
Ethiopia and Nigeria. The sub-analysis stratified by HIV was
therefore admittedly underpowered and prone to self-selection
bias, and it is difficult to interpret. The results, however, are
included to provide preliminary information on the potential
performance of the schemes in this patient population.
Protocol Registration and Ethical Approval
The protocol (International Standard Randomized Controlled
Trial Number Register ISRCTN53339491) was approved by the
WHO Ethics Review Committee, the Liverpool School of
Tropical Medicine Ethics Research Committee, and the national
and institutional ethics committees of the four countries. Consent
and information sheets were translated, and informed witnessed
written or oral consent was obtained.
Results
Characteristics of Participants
A total of 6,627 patients (1,909 in Ethiopia, 630 in Nepal, 1,238
in Nigeria, and 2,850 in Yemen) were enrolled. Of these, 3,053
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(46.1%) were screened with the frontloaded and 3,574 (53.9%)
with the standard scheme. The characteristics of the participants
are shown in Table 1, stratified by study arm. There were no
statistically significant differences between the participants as-
signed to the SSM and SMS study arms in any of the four sites
(countries). Patients in Yemen and Nepal were older than patients
in Ethiopia and Nigeria, while patients in Ethiopia and Yemen
(47.7% and 49.2%) were more likely to come from rural areas than
patients in Nepal and Nigeria (10.2% and 13.2%). Patients from
Nepal had longer cough duration at the time of consultation than
patients enrolled at the other sites. The most frequent symptoms,
besides cough, were chest pains (79.1%), weight loss (70.5%), and
fever (70.2%). Only 1.1% of patients in Yemen, 2.6% in Nepal,
22.6% in Ethiopia, and 54.1% in Nigeria knew their HIV status.
Among patients who reported their HIV status, patients in Nigeria
were more likely to be HIV-positive (71.3%) than those in Ethiopia
(23.7%), Nepal (12.5%), and Yemen (3.0%).
Completeness of Specimen Submission and Sputum
Grades
Figure 2 presents the number of patients who submitted one, the
first two, and all three specimens requested, by collection scheme.
Patients following the SSM scheme were more likely to submit the
first two specimens than patients following the SMS scheme
(97.6% versus 94.2%; difference 3.4%, 95% CI 2.3%–4.6%).
Although the waiting time for the second specimen in the SSM
scheme was only one hour, some patients still left the clinic without
submitting this specimen. The proportion of patients submitting all
three smears did not differ significantly for patients screened with
the SSM and SMS schemes (94.1% versus 92.8%, respectively;
difference 1.2%, 95% CI 20.4% to 2.8%). The proportion of
patients with one or more positive smear results by study site and
scheme is shown in Table 1. Overall, 582 (19.1%) of the 3,053
patients examined using the SSM scheme were smear-positive,
compared to 642 (18.0%) of 3,574 examined using the SMS
scheme (p=0.5). Spot specimens were more likely to have low
smear grades (‘‘scanty’’ [,10 AFB per 100 fields] or ‘‘+’’ [10–99
AFB per 100 fields]) (9.0%/9.0% for SSM and 9.0%/8.1% for
SMS, respectively) than the morning specimens (6.9% for both
schemes). The lower AFB grades of the spot specimens resulted in
a slightly higher proportion of morning specimens being graded as
positive (16.4% and 16.8% of the morning specimens versus
14.6% and 15.3% of first-spot specimens of the SSM and SMS
schemes, respectively).
Sensitivity and Specificity of SSM and SMS Schemes
Sputum specimens of 6,467 (97.6%) of the patients enrolled
were cultured, and 1,561 (24.1%) were culture-positive. The ITT
analysis was conducted in 6,358 patients (2,929 SSM and 3,429
SMS), as shown in Table 2. SSM identified 500 of 712 culture-
Table 1. Demographic and clinical characteristics of participants.
Characteristic Ethiopia Nepal Nigeria Yemen
SSM (n=879) SMS (n=1,030) SSM (n=347) SMS (n=283) SMS (n=582) SSM (n=656) SMS (n=1,245) SSM (n=1,605)
Age (SD), in years 33.7 (14.1) 34.4 (14.6) 43.3 (17.4) 44.5 (18.0) 34.4 (10.7) 33.7 (10.8) 42.0 (18.4) 41.7 (17.6)
Male sexa (%) 459 (52.8%) 563 (55.0%) 218 (62.8%) 184 (65.0%) 296 (51.9%) 294 (44.8%) 629 (50.5%) 798 (49.7%)
Residence
Urban 510 (58.0%) 443 (44.3%) 301 (86.7%) 265 (95.4%) 500 (85.9%) 557 (84.9%) 626 (50.3%) 821 (51.1%)
Rural 355 (40%) 556 (45.9%) 46 (13.3%) 18 (6.4%) 74 (12.9%) 89 (13.9%) 619 (49.7%) 784 (48.9%)
Unknown 14 (2%) 31 (10%) 0 0 8 (1.4%) 10 (1.5%) 0 0
Illiterate 427 (49.7%) 494 (50.7%) 107 (30.8%) 93 (32.9%) 44 (7.6%) 51 (7.8%) 798 (64.1%) 1,024 (63.8%)
Signs/symptoms
Cough durationb 8.4 (11.5) 8.1 (11.2) 13.7 (17.0) 12.3 (13.4) 9.9 (18.7) 8.4 (14.7) 8.8 (14.1) 9.1 (14.3)
Chest pain 709 (81%) 766 (74%) 261 (75.2%) 227 (80.2%) 363 (63.4%) 402 (61.3%) 1,102 (88.5%) 1,410 (87.9%)
Weight loss 589 (67%) 63 (62%) 224 (64.6%) 168 (59.4%) 376 (64.6%) 436 (66.5%) 978 (78.6%) 1,270 (79.1%)
Fever 582 (66%) 660 (64%) 167 (48.1%) 124 (43.8%) 392 (67.4%) 435 (66.3%) 1,001 (80.4%) 1,290 (80.4%)
Night sweats 680 (77%) 762 (74%) 167 (48.1%) 139 (49.1%) 254 (43.6%) 289 (44.5%) 930 (74.7%) 1,165 (72.6%)
Loss of appetite 537 (61%) 665 (65%) 229 (66.0%) 186 (65.7%) 265 (45.5%) 292 (44.5%) 878 (70.5%) 1,117 (69.6%)
HIV status
Positive 54 (6%) 47 (5%) 1 (0.3%) 1 (0.4%) 244 (41.9%) 241 (36.8%) 0 (0%) 1 (0.1%)
Negative 140 (16%) 186 (18%) 8 (2.3%) 6 (2.1%) 81 (13.9%) 114 (17.4%) 14 (1.1%) 18 (1.1%)
Not known 685 (78%) 797 (77%) 338 (97.4%) 276 (97.5%) 257 (44.2%) 301 (45.8%) 1,231 (98.9%) 1,586 (98.8%)
Culture
Positive 274 (31%) 312 (30.3%) 36 (10.4%) 38 (13.4%) 119 (20.4%) 114 (17.4%) 283 (22.7%) 385 (24.0%)
Negative 540 (61%) 644 (62.5%) 289 (83.3%) 236 (83.4%) 447 (76.8%) 516 (78.7%) 941 (75.6%) 1,184 (73.8%)
Contaminated 13 (1%) 15 (1.5%) 20 (5.8%) 8 (2.8%) 7 (1.2%) 15 (2.3%) 10 (0.8%) 20 (1.2%)
Not available 52 (6%) 59 (5.7%) 2 (0.6%) 1 (0.4%) 9 (1.6%) 11 (1.7%) 11 (0.9%) 16 (1.0%)
Smear positive 211 (24.0%) 236 (22.9%) 36 (10.4%) 36 (12.7%) 116 (19.9%) 93 (14.2%) 219 (17.6%) 277 (17.3%)
aSex unknown for 75 patients in Ethiopia, 22 in Nigeria and 33 in Nepal. There were no statistical differences between the study arms in any of the four countries.
bMean (SD), in weeks.
doi:10.1371/journal.pmed.1000443.t001
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positive patients (sensitivity 70.2%, 95% CI 66.5%–73.9%), and
SMS identified 559 of 849 culture-positive patients (sensitivity
65.9%, 95% CI 62.3%–69.5%). The difference in sensitivity (SSM
minus SMS) was 4.3% (95% CI for the difference = 0.6% to
9.0%), indicating that the sensitivity of SSM was non-inferior to
the sensitivity of the SMS scheme. SSM had a specificity of 96.9%
(95% CI 93.2%–99.9%), with 2,149 of 2,217 culture-negative
patients being smear-negative, compared to 2,518 of 2,580
(97.6%, 95% CI 94.0%–99.9%) patients examined with the
SMS scheme. The difference was 20.7% (95% CI 21.9% to
0.4%), indicating that the specificity of SSM was non-inferior to
the specificity of SMS.
The same 6,358 patients were included in the ITT analysis of
the first two smears. SS identified 453 of 712 culture-positive
patients (sensitivity = 63.6%, 95% CI 59.7%–67.5%), while SM
identified 550 of 849 culture-positive patients (sensitivity = 64.8%,
95% CI 61.3%–68.3%). The difference in sensitivity (SS minus
SM) was 21.2% (95% CI for the difference =23.9% to 6.4%),
indicating that the sensitivity of SS was non-inferior to that of the
SM scheme, as the lower limit of the 95% CI does not exceed the
predefined non-inferiority limit of 25%. The specificity of SS
(97.4%, 95% CI 93.5%–99.9%) was not inferior to the specificity
of the SM scheme (97.8%, 95% CI 94.3%–99.9%). The difference
in specificity between the schemes was 20.4% (95% CI 21.4% to
0.6%), indicating that the specificity of SS was non-inferior to the
specificity of SM. The PPA results were similar to those of the ITT
analysis (Table 2). If the smears collected only on the first day were
included (SS for SSM and S for SMS), the sensitivity of SS (63.6%,
95% CI 59.7%–67.5%) was higher than the sensitivity of the first S
specimen of the SMS scheme (466/845; 55.1%, 95% CI 51.7%–
58.5%), while the specificities were similar (97.4%, 95% CI
93.5%–99.9%, and 98.5%, 95% CI 97.9%–98.9%, respectively).
The numbers of patients that would be missed or correctly
identified by the schemes for each 1,000 patients screened are
indicated in Table 3. These parameters were calculated using the
24.1% culture positivity obtained and the sensitivity and specificity
of the PPA and ITT analysis. Using the ITT parameters, three
specimens collected with the SSM and SMS schemes would result
in 90.4% and 90.0% of patients, respectively, being correctly
classified, while the SS and SM smears would result in 89.2% and
89.8% of patients, respectively, being correctly classified. The
results obtained with the PPA were similar to those obtained with
the ITT analysis.
In total, 1,059 patients reported their HIV status. The sensitivity
(ITT) of the three-smear schemes decreased from 81.5% among
HIV-negative to 71.2% among HIV-positive patients under the
SSM scheme and from 68.8% to 51.8% under the SMS scheme.
HIV co-infection thus seemed to reduce the sensitivity of smear
microscopy independently of the scheme, although, as stated, the
study was underpowered for this sub-analysis.
Figure 2. Number of patients submitting the first, the first two, and all three specimens, by scheme. Error bars represent the upper limit
of the 95% confidence limits.
doi:10.1371/journal.pmed.1000443.g002
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Discussion
TB is a disease of poverty and a global public health emergency
[1]. Patients with chronic cough are the main source of infection,
and their early identification and treatment are key to effective
control [1]. Simple diagnostics suitable for community-based
health services would significantly improve TB control activities
but unfortunately are not expected to be available in the near
future [16]. Smear microscopy thus remains the test most widely
used for diagnosis in LMICs.
Examining sputum smears is relatively simple, and approxi-
mately 50 million patients are investigated by smear microscopy
each year. Between 70% and 90% of these examinations take
place in 22 high-TB burden countries [21], where 60% of the
population lives on less than US$2.00/day. Patients in these
settings often travel to diagnostic centres, where they are faced
with a process lasting several days and necessitating further
expenditure. Although drop-out rates among patients undertaking
smear microscopy are infrequently reported, 13% of patients in
Table 2. Sensitivity and specificity of two and three smears, stratified by scheme by intention to treat and per protocol analysis.
Scheme Smear Resulta Culture Sensitivity (95% CI) Specificity (95% CI)
Positive Negative
ITT
SS Positive 453 (63.6) 57 (2.6) 63.6% (59.7%–67.5%) 97.4% (93.5%–99.9%)
Negative 259 (36.4) 2,160 (97.4)
SM Positive 550 (64.8) 56 (2.2) 64.8% (61.3%–68.3%) 97.8% (94.3%–99.9)
Negative 299 (35.2) 2,524 (97.8)
SSM Positive 500 (70.2) 68 (3.1) 70.2% (66.5%–73.9%) 96.9% (93.2%–99.9%)
Negative 212 (29.8) 2,149 (96.9)
SMS Positive 559 (65.8) 62 (2.4) 65.9% (62.3%–69.5%) 97.6% (94.0%–99.9%)
Negative 290 (34.1) 2,518 (97.6)
PPA
SS Positive 447 (63.6) 45 (2.4) 63.6% (59.6%–67.6%) 97.6% (93.6%–99.9%)
Negative 256 (36.4) 2,121(97.6)
SM Positive 535 (65.0) 54 (2.2) 65% (61.6%–68.4%) 97.8% (94.4%–99.9%)
Negative 288 (35.0) 2,385 (97.8)
SSM Positive 485 (70.6) 63 (3.0) 70.6% (66.7%–74.5%) 97% (93.1%–99.9%)
Negative 202 (29.4) 2,024 (97)
SMS Positive 542 (66.4) 60 (2.5) 66.4% (62.9%–69.9%) 97.5% (94.0%–99.9%)
Negative 274 (33.6) 2,340 (97.5)
aSmear-positive defined as having $1 smear with $1 AFB. Patients with missing smears were classified according to the smears available (e.g., a patient with first spot
sample negative and morning sample missing was classified as negative) for ITT analysis.
doi:10.1371/journal.pmed.1000443.t002
Table 3. Number of patients that would be correctly identified by each smear microscopy scheme using the PPA and ITT analysis.
Scheme Sensitivity Specificity 1,000 Patients Correctly Identified, n (%)
Culture-Positive, n=241
(24.1%)
Culture-Negative, n=759
(75.9%)
Smear-Positive Missed Smear-Negative Missed
PPA
SSM 70.6% 97.0% 170 71 736 23 906 (90.6%)
SS 63.6% 97.6% 153 88 741 18 894 (89.4%)
SMS 66.4% 97.5% 160 81 740 19 900 (90.0%)
SM 65.0% 97.8% 157 84 742 17 899 (89.9%)
ITT
SSM 70.2% 96.9% 169 72 735 24 904 (90.4%)
SS 63.6% 97.4% 153 88 739 20 892 (89.2%)
SMS 65.9% 97.6% 159 82 741 18 900 (90.0%)
SM 64.8% 97.8% 156 85 742 17 898 (89.8%)
doi:10.1371/journal.pmed.1000443.t003
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Chennai, India, 37% in Lilongwe, Malawi, and 95% in Lusaka,
Zambia, fail to complete the process [6–8]. Furthermore, between
5% (e.g., Pakistan [22]) and 52% (e.g., Cape Town, South Africa
[23]) of cases with smear-positive pulmonary TB default the
diagnostic process after submission of the first specimen [22–27].
These percentages are likely to be underestimates, as most reports
used the old case definition requiring two or more positive smears
to classify a case as smear-positive. Defaulting patients have a high
mortality rate in low-resource settings [23,27], and reducing the
number of visits required could increase the acceptability of and
adherence to the diagnostic process and reduce mortality.
Currently, most patients requested to provide SMS specimens
receive the results of all sputum examinations the next day of
consultation, or later. If the first sputum examination is positive
but the patient does not return the next day, the patient does not
receive any of the results and is lost. Schemes that facilitate the
identification of the majority of smear-positive patients and
provide these results on the first day of consultation therefore
have the potential to benefit large numbers of patients.
The proportion of patients who failed to complete the
submission of all specimens during this study was lower than
under operational conditions. Even so, participants in the SSM
arm were more likely to submit their first two sputum samples
compared to participants in the SMS arm, and the scheme could
be implemented in a way that allows patients to return later in the
day to receive laboratory results and referral for treatment. As
most smear-positive patients were identified by the first two
smears, a higher number of patients could be referred for
treatment, with significant operational advantages in locations
where many patients abandon the diagnostic process.
The SSM scheme has sensitivity and specificity that is not-
inferior to the SMS scheme used in most LMICs. Similarly, the
two-specimen SS scheme sensitivity was not inferior to that of the
two-specimen SM scheme, and the losses in sensitivity from the
three- to the two-specimen scheme are within the range predicted
by a systematic review (0%–10% losses) [9]. Using two spot
specimens in this study resulted in up to 7% lower sensitivity than
using the SSM scheme. NTPs with overburdened laboratories that
screen patients following the WHO recommendation of examining
two smears [28] thus could consider collecting two on-the-spot
specimens if a significant proportion of patients default from the
diagnostic process, as the lower drop-out in patient numbers would
at least compensate for the loss in sensitivity. In addition,
programmes that decided to continue collecting three specimens
could use a SSM scheme and identify most smear-positive cases
the first day of consultation. This seemingly small intervention
therefore has the potential to reduce losses to follow up in areas
where a significant proportion of patients fail to return for the
second day of sputum submission. SS schemes may also be very
useful in combination with new diagnostics with higher sensitivity,
such as the new automated nuclear acid amplification tests [29].
The WHO-endorsed Xpert tests (Cepheid) are likely to be used
mostly in patients with negative smear microscopy, and the rapid
screening of patients that require further testing would be key for
avoiding delays in the diagnostic process.
There are limitations and aspects that merit further monitoring
to ascertain whether the trial results can be replicated under more
realistic programmatic conditions. There has been considerable
discussion in the scientific literature as to whether non-inferiority
trials provide the same quality of evidence than superiority trials
[30]. Non-inferiority trials often require smaller sample sizes, and
systematic biases usually influence the results towards finding non-
inferiority [31]. Superiority trials, in turn, require larger sample
sizes than non-inferiority studies and therefore require resources
that are often out of reach for interventions with low commercial
value. Although the study was conducted using randomization
procedures that were homogeneous across study sites and strict
blinding of smear gradings, non-quantified biases beyond the
control of the investigators may have influenced these results.
There was also an unequal number of participants in the two
schemes, which resulted from nine ‘‘frontloaded’’ weeks falling on
weeks with public holidays (Christmas/New Year and Eid)
compared to only one of the ‘‘standard’’ weeks. Recruitment
was very low during these weeks, and because of this, together with
the fact that an additional six weeks were allocated to the standard
scheme, we enrolled unequal numbers. Further still, the study may
have been underpowered, given the assumption that 50% of
screened cases would be culture-positive, whereas only 24% were
positive. Despite these limitations, the strikingly similar differences
in sensitivity and specificity observed under the ITT analysis and
PPA strengthen the conclusions that can be drawn from the
findings.
HIV testing was not offered routinely to all study participants.
Unfortunately, this service was not available for all patients in
Yemen and Nepal, and the uptake of HIV testing varied
significantly between Ethiopia and Nigeria. Patients with severe
TB symptoms were more likely to take up HIV testing than
patients with milder clinical presentation; thus, patients accepting
these tests in Ethiopia and Nigeria may have had more advanced
stages of TB. The data analysis stratified by HIV status is therefore
prone to bias and needs to be considered as only a rough
indication of the performance of the scheme in this population.
Although the data suggest that the two schemes had similar
sensitivity in the study patients, the sensitivity could had been
different if all patients had been tested for HIV.
The decision to adopt these schemes needs to consider the
greater bacillary yield of the morning sample, the potential burden
on laboratory technicians to provide results the same day to start
treatment, and the potential inconvenience and nosocomial
exposure involved in having the patient wait at the health care
facility an hour to give a second spot sample. While providing
results the same day sounds attractive, further evidence is needed
to demonstrate that it is feasible to implement the scheme under
programmatic conditions. This would be specially challenging in
rural and remote areas and primary health care clinics where
potential TB patients may find it hardest to access clinics and
where capacity to undertake smear examinations may not be
available on site. The implementation of a SSM scheme would
therefore require changes to the provision of services, including
on-site laboratory with a same-day turn-around time, services that
enable the initiation or referral of patients for treatment at the time
that results become available, and, in high HIV prevalence areas,
services to minimize contact between patients, and thus minimize
the risk of nosocomial infection, by collecting the first specimen
during the triage stage, collecting the second specimen one hour
later, and asking the patient to return to the clinic in the afternoon.
Operational research is also needed to monitor the performance
of the schemes. For example, smears were examined blindly to
ensure data quality, but this routine also prevented staff copying
the results of a patient’s previous slides for that patient’s
subsequent slides, which is a practice widely suspected in
overburdened laboratories and reported anecdotally [32]. As
technicians may remember the results of uncovered smears
collected in quick succession, they may be less motivated to
examine a second or third smear if the first sputum is negative.
There is also no evidence about whether early diagnosis results in
increased treatment uptake, decreased mortality, or improved
uptake of HIV testing or ART for HIV [33–36].
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In summary, a scheme consisting of two smears collected one
hour apart followed by a morning specimen identifies as many
smear-positive patients as the standard SMS scheme, and patients
were more likely to submit the first two specimens. The
examination of the first two specimens identified the majority of
smear-positive patients, independently of the scheme. Two spot
specimens did not have sensitivity inferior to two specimens
collected as spot and morning, and the former combination could
be more suitable for locations where patients are likely to default
from the diagnostic process. Smear microscopy had reduced
sensitivity in patients co-infected with HIV, but this loss seemed to
be independent of the scheme.
The identification of the majority of smear-positive patients may
require no more than one patient visit, and the scheme presented
here has the potential to improve the diagnosis of pulmonary TB
in LMICs [16]. A single-visit diagnosis would represent a
substantial opportunity to improve the delivery of TB services,
particularly to the poor.
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Editors’ Summary
Background. Every year, nearly 10 million people develop
tuberculosis—a contagious bacterial infection that usually
affects the lungs (pulmonary tuberculosis)—and about 1.7
million people die from the disease. Mycobacterium
tuberculosis, which causes tuberculosis, is spread in
airborne droplets when people with the disease cough or
sneeze. Thus, to control tuberculosis, it is essential that
infected individuals are rapidly identified and treated. The
‘‘gold standard’’ diagnostic test for tuberculosis is
mycobacterial culture, in which laboratory staff try to grow
M. tuberculosis from sputum (mucus brought up from the
lungs by coughing). However, although this test is sensitive
(it detects most patients with tuberculosis) and has a high
specificity (a low rate of false-positive results), it is too slow
to produce results and too complex for routine use in the
low- and middle-income countries where tuberculosis mainly
occurs. In these countries, patients are usually investigated
using direct sputum smear microscopy, a cheaper but less
sensitive test in which multiple sputum samples treated with
the acid-fast Ziehl-Neelsen stain are examined for the
presence of M. tuberculosis bacilli.
Why Was This Study Done? In most national tuberculosis
control programs, patients provide an ‘‘on the spot’’
specimen during their initial consultation, a specimen
collected at home the next morning, and another on-the-
spot specimen when they bring their morning specimen to
the clinic (a ‘‘spot-morning-spot,’’ or SMS, collection scheme).
Unfortunately, patients often fail to return with their
morning sample. Furthermore, the examination of three
samples strains the limited laboratory resources of
developing countries. Based on several recent reviews, the
World Health Organization recently recommended that only
two samples need be examined, a policy change that
reduces the laboratory workload but does not avoid the
problems of collecting a morning sample and patient drop-
out during the diagnostic process. In this non-inferiority,
cluster randomized trial, the researchers compare the
sensitivity and specificity of a spot-spot-morning (SSM; two
on-the-spot specimens collected during the first clinic visit
an hour apart, and a third specimen collected at home the
next morning) scheme for tuberculosis diagnosis with those
of the standard SMS scheme. A non-inferiority trial
investigates whether an intervention is not worse than a
control intervention; a cluster randomized trial randomly
assigns groups of patients rather than individual patients to
the test and control interventions.
What Did the Researchers Do and Find? The researchers
enrolled 6,627 patients in Ethiopia, Nepal, Nigeria, and
Yemen who had had a cough for more than two weeks (a
characteristic symptom of tuberculosis). A quarter of the
patients had culture-positive tuberculosis. The centers
participating in the study were randomly assigned each
week for a year to use either the SMS or the SSM sample
collection scheme. Compared to mycobacterial culture, the
sensitivities of the SSM and SMS schemes were 70.2% and
65.9%, respectively, which indicates that the new scheme
was non-inferior to the SMS scheme. Similarly, the specificity
of SSM (96.9%) was non-inferior to that of SMS (97.6%).
Importantly, the sensitivity of diagnosis using just the first
two samples collected in the SSM scheme was also non-
inferior to the sensitivity of diagnosis using the first two
samples collected in the SMS scheme (63.6% versus 64.8%;
the researchers defined non-inferiority of SSM as a difference
in its sensitivity compared to that of SMS of less than 25%).
Finally, patients tested using the SSM scheme were more
likely to provide the first two samples than patients tested
using the SMS scheme (98% versus 94.2%).
What Do These Findings Mean? These findings suggest
that a sputum collection scheme in which two samples are
collected one hour apart followed by a morning specimen
could identify as many smear-positive patients as the
standard SMS scheme. Importantly, they also indicate that
examination of the first two specimens alone identifies most
smear-positive patients independently of which scheme is
used. These findings suggest that the SSM scheme might be
more suitable for tuberculosis diagnosis than the SMS
scheme in locations where patients are likely to drop out
of the diagnosis process (for example, in low- and middle-
income countries, where patients often live a long way from
clinics). However, for an SSM scheme to work effectively, an
on-site laboratory with a same-day turn-around service will
be essential, and tuberculosis clinics will need to minimize
contact between patients waiting to provide their second
on-the-spot specimen.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000443.
N A related PLoS Medicine Research Article by Cuevas et al.
uses LED fluorescence microscopy for the diagnosis of
pulmonary tuberculosis
N The World Health Organization provides information on all
aspects of tuberculosis, including information on tubercu-
losis diagnostics and on the recommendation to reduce
the number of smears for diagnosis to two; the Stop TB
Partnership provides information on global tuberculosis
control (some information in several languages)
N The US Centers for Disease Control and Prevention has
information about tuberculosis, including information on
the diagnosis of tuberculosis disease
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
N A new Web site dedicated to the discussion and
optimization of smear microscopy has recently been
launched
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